Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | GFER | P55789 | 4/20 | 0.53 |
| ▸ | THRB | P10828 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PLEC | Q15149 | 1/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.51 |
| ▸ | CDC25B | P30305 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14190740 | 0.85 | PRKCI (0.53) | PRKCIGAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL27111060 | 0.85 | PRKCI (0.73) | PRKCIMAPTNPC1RAB9AKMT2A | |
| SCHEMBL1067119 | 0.85 | PRKCI (0.73) | PRKCIGAAMAPTKDM4EALDH1A1 | |
| SCHEMBL2248360 | 0.83 | PRKCI (0.51) | PRKCITHRBHPGDHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL18691959 | 0.83 | PRKCI (0.71) | PRKCIGAAMAPTKDM4EALDH1A1 | |
| SCHEMBL23346408 | 0.82 | MAPT (0.65) | GAAMAPTKDM4EALDH1A1GFER | |
| SCHEMBL2890452 | 0.82 | HCAR3 (0.61) | PRKCIGAAMAPTKDM4EALDH1A1 | |
| SCHEMBL15942895 | 0.81 | HDAC1 (0.61) | GAAMAPTKDM4EALDH1A1GFER | |
| SCHEMBL222734 | 0.81 | KDM4E (0.59) | PRKCIGAAMAPTKDM4EALDH1A1 | |
| SCHEMBL6187233 | 0.80 | HCAR3 (0.55) | GAAMAPTKDM4EALDH1A1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109232535-A | A kind of preparation method of non-peptide batroxobin inhibitor dabigatran etcxilate | 重庆奥舍生物化工有限公司 | 2019-01-18 | — | — | CN | claimed |
| CN-108864047-A | A kind of preparation method of non-peptide batroxobin inhibitor dabigatran etcxilate | 河南师范大学 | 2018-11-23 | — | — | CN | claimed |
| CN-109232535-A | A kind of preparation method of non-peptide batroxobin inhibitor dabigatran etcxilate | 重庆奥舍生物化工有限公司 | 2019-01-18 | — | — | CN | disclosed |
| CN-108864047-A | A kind of preparation method of non-peptide batroxobin inhibitor dabigatran etcxilate | 河南师范大学 | 2018-11-23 | — | — | CN | disclosed |
| US-9453051-B2 | Cyclosporin derivatives | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2016-09-27 | — | — | US | disclosed |
| EP-2751127-B1 | CYCLOSPORIN DERIVATIVES | MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V (DE) | 2016-07-27 | — | — | EP | disclosed |
| US-20140316104-A1 | CYCLOSPORIN DERIVATIVES | LEAD DISCOVER CENTER GMBH (DE) | 2014-10-23 | — | — | US | disclosed |
| EP-2751127-A1 | CYCLOSPORIN DERIVATIVES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften (DE) | 2014-07-09 | — | — | EP | disclosed |
| CN-103842372-A | Cyclosporin derivatives | MAX PLANCK GESELLSCHAFT | 2014-06-04 | — | — | CN | disclosed |
| WO-2013030208-A1 | CYCLOSPORIN DERIVATIVES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-03-07 | — | — | WO | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2008082490-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008082490-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
| EP-1117651-A1 | NEW BIS-BENZIMIDAZOLES | Bayer Aktiengesellschaft (DE) | 2001-07-25 | — | — | EP | disclosed |
| CN-1251579-A | Compound and compositions for treating diseases associated with serine protease, particularly tryptase, activity | AXYS PHARM CORP (US) | 2000-04-26 | — | — | CN | disclosed |
| WO-2000020400-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATING HEPATITIS C INFECTIONS | AXYS PHARMACEUTICALS, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000020401-A1 | NEW BIS-BENZIMIDAZOLES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | PRKCI 3615/4885GAA 69/4885MAPT 2104/4885 |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | PRKCI 287/4885GAA 3921/4885MAPT 1863/4885 |
| US-20140316104-A1 | CYCLOSPORIN DERIVATIVES | CHP1, RYR2, CANX | PRKCI 1278/4885GAA 3679/4885MAPT 1585/4885 |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | PRKCI 2660/4885GAA 181/4885MAPT 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.